Clinical Trial Update: A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of HJ-004-02 tablets in patients with non-squamous non-smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HJ-004-02

Snippet

Sponsor: Tongji University | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Status: RECRUITING